Unlocking the Drivers of Nanoparticle Delivery

Despite their potential, nanoparticle therapies have yet to make a significant clinical impact for most cancer patients. Our goal is to change this by identifying and validating nanoparticle-specific biomarkers. This approach will enable us to stratify patients more effectively and develop tailored formulations that can benefit those with the most challenging-to-treat tumors.

We have leveraged pooled screening techniques to uncover hundreds of predictive biomarkers of nanoparticle-cell interactions. We are now expanding this methodology to encompass a wider range of nanoparticles with diverse drug cargos, aiming to pinpoint the most promising biomarkers for clinical translation. Through rigorous study of the biologic regulators of nanoparticle delivery, we aim to accelerate the translation of nanoparticle therapies into the clinic, offering new hope for patients with difficult-to-treat cancers.